Drug Profile
AN 2898
Alternative Names: AN-2898Latest Information Update: 04 Aug 2015
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals
- Class Anti-inflammatories; Antipsoriatics; Nitriles; Organic boron compounds; Phenyl ethers; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Psoriasis
Most Recent Events
- 07 Feb 2012 Final efficacy and adverse events data from a phase IIa trial in Atopic dermatitis released by Anacor
- 12 Dec 2011 Preliminary efficacy data from a phase IIa trial in Atopic dermatitis released by Anacor
- 12 Oct 2011 Anacor Pharmaceuticals completes enrolment in its phase II trial for Atopic dermatitis in Australia (NCT01301508)